Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage

Brain Research Bulletin

Volumn 81, Issue 1, 2010, Pages 191-195

  Satoh, Shin ichi ^a   Hitomi, Asako ^a   Ikegaki, Ichiro ^a   Kawasaki, Koh ^a   Nakazono, Osamu ^a   Iwasaki, Masakazu ^a   Mohri, Mitsunobu ^a   Asano, Toshio ^a  

^a ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Cerebral ischemia; Endothelial damage dysfunction; Fasudil; Hydroxyfasudil; Rho kinase

Indexed keywords

FASUDIL; HYDROXYFASUDIL; RHO KINASE INHIBITOR; THROMBIN; THROMBOPLASTIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD VESSEL PERMEABILITY; BRAIN DAMAGE; BRAIN FUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL CULTURE; CELL SURFACE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INTERNAL CAROTID ARTERY; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STROKE; TREATMENT DURATION; TREATMENT OUTCOME; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BRAIN; BRAIN ISCHEMIA; CAPILLARY PERMEABILITY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM; ENZYME INHIBITORS; HUMANS; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RHO-ASSOCIATED KINASES; STROKE; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 71349088554     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2009.08.021     Document Type: Article

References (28)

1. Akopov S., Sercombe R., and Seylaz J. Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Cerebrovasc. Brain Metab. Rev. 8 (1996) 11-94
2. Birukova A.A., Smurova K., Birukov K.G., Kaibuchi K., Garcia J.G.N., and Verin A.D. Role of Rho GTPases in thrombin-induced lung vascular endothelial cells barrier dysfunction. Microvasc. Res. 67 (2004) 64-77
3. Breslin J.W., and Yuan S.Y. Involvement of RhoA and Rho kinase in neutrophil-stimulated endothelial hyperpermeability. Am. J. Physiol. 286 (2004) H1057-H1062
4. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., and Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo. Circ. Res. 93 (2003) 767-775
5. Hitomi A., Satoh S., Ikegaki I., Suzuki Y., Shibuya M., and Asano T. Hemorheological abnormalities in experimental cerebral ischemia and effects of protein kinase inhibitor on blood fluidity. Life Sci. 67 (2000) 1929-1939
6. Ishibashi T., Sakamoto T., Ohkawara H., Nagata K., Sugimoto K., Sakurada S., Sugimoto N., Watanabe A., Yokoyama K., Sakamoto N., Kurabayashi M., Takuwa Y., and Maruyama Y. Integral role of Rho A activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 681-687
7. Kappelmayer J., Berecki D., Misz M., Olah L., Fekete I., Csiba L., and Blasko G. Monocytes express tissue factor in young patients with cerebral ischemia. Cerebrovasc. Dis. 8 (1998) 235-239
8. Liu X.S., Zhang Z.G., Zhang L., Morris D.C., Kapke A., Lu M., and Chopp M. Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J. Cereb. Blood Flow Metab. 26 (2006) 787-796
9. Mechtcheriakova D., Schabbauer G., Lucerna M., Clauss M., de Martin R., Binder B.R., and Hofer E. Specificity, diversity, and convergence in VEGF and TNF-α signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J. 15 (2001) 230-242
10. Nagata K., Ishibashi T., Sakamoto T., Ohkawara H., Shindo J., Yokoyama K., Sugimoto K., Sakurada S., Takuwa Y., Nakamura S., Teramoto T., and Maruyama Y. Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis 163 (2002) 39-47
11. Osuka K., Suzuki Y., Tanazawa T., Hattori K., Yamamoto N., Takayasu M., Shibuya M., and Yoshida J. Interleukin-6 and development of vasospasm after subarachnoid haemorrhage. Acta. Neurochir. (Wien) 140 (1998) 943-951
12. Pearson J.D. Endothelial cell function and thrombosis. Bailliere's Best Pract. Res. Clin. Haematol. 12 (1999) 329-341
13. Rikitake Y., Kim H.H., Huang Z., Seto M., Yano K., Asano T., Moskowitz M.A., and Liao J.K. Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36 (2005) 2251-2257
14. Satoh S., Ikegaki I., Suzuki Y., Asano T., Shibuya M., and Hidaka H. Neuroprotective properties of a protein kinase inhibitor against ischaemia-induced neuronal damage in rats and gerbils. Br. J. Pharmacol. 118 (1996) 1592-1596
15. Satoh S., Kobayashi T., Hitomi A., Ikegaki I., Suzuki Y., Shibuya M., Yoshida J., and Asano T. Inhibition of neutrophil migration by a protein kinase inhibitor for the treatment of ischemic brain infarction. Jpn. J. Pharmacol. 80 (1999) 41-48
16. Satoh S., Toshima Y., Hitomi A., Ikegaki I., Seto M., and Asano T. Wide therapeutic time window for Rho-kinase inhibition therapy in ischemic brain damage in a rat cerebral thrombosis model. Brain Res. 1193 (2008) 102-108
17. Satoh S., Utsunomiya T., Tsurui K., Kobayashi T., Ikegaki I., Sasaki Y., and Asano T. Pharmacological profile of hydroxyl fasudil as a selective rho kinase inhibitor on ischemic brain damage. Life Sci. 69 (2001) 1441-1453
18. Shibuya M., Hirai S., Seto M., Satoh S., and Ohtomo E. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J. Neurol. Sci. 238 (2005) 31-39
19. Suzuki Y., Shibuya M., Satoh S., Sugimoto Y., and Takakura K. A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg. Neurol. 68 (2007) 126-132
20. Suzuki Y., Shibuya M., Satoh S., Sugiyama H., Seto M., and Takakura K. Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol. Med. Chir. (Tokyo) 48 (2008) 241-248
21. Takemoto M., Sun J., Hiroki J., Shimokawa H., and Liao J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106 (2002) 57-62
22. Thomas W.S., Mori E., Copeland B.R., Yu J.-Q., Morrissey J.H., and del Zoppo G.J. Tissue factor contributes to microvascular defects after focal cerebral ischemia. Stroke 24 (1993) 847-854
23. Toshima Y., Satoh S., Ikegaki I., and Asano T. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 31 (2000) 2245-2250
24. Van Hinsbergh V.W.M., and Van Nieuw Amerongen G.P. Intracellular signalling involved in modulating human endothelial barrier function. J. Anat. 200 (2002) 549-560
25. Yamaguchi S., Tanabe K., Takai S., Nishiwaki R.M., Adachi S., Iida H., Kozawa O., and Dohi S. Involvement of Rho-kinase in tumor necrosis factor-α-induced interleukin-6 release from C6 glioma cells. Neurochem. Int. 55 (2009) 438-445
26. Yano K., Kawasaki K., Hattori T., Tawara S., Toshima Y., Ikegaki I., Sasaki Y., Satoh S., Asano T., and Seto M. Demonstration of elevation and localization of Rho-kinase activity in the brain of a rat model of cerebral infarction. Eur. J. Pharmacol. 594 (2008) 77-83
27. Zhang J.J., Kelm R.J., Biswas P., Kashgarian M., and Madri J.A. PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells. J. Cell. Physiol. 210 (2007) 527-537
28. Zhang L., Zhang Z.G., Ding G.L., Jiang Q., Liu X., Meng H., Hozeska A., Zhang C., Li L., Morris D., Zhang R.L., Lu M., and Chopp M. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 112 (2005) 3486-3494